EGFR and non-small cell lung carcinoma: KEYNOTE-010 included a small number of EGFRm advanced NSCLC patients (9%) who were randomized to receive 2mg/kg pembrolizumab, 10mg/kg pembrolizumab, or 75 mg/m2 docetaxel every three weeks after having progressed on at least two cycles of platinum-based chemotherapy and treatment with an EGFR TKI.